Skip to main content
Litigation Update: Dr. Reddy's vs. Novo Nordisk (Semaglutide)

Litigation Update • December 12, 2025

Delhi High Court Clears Dr. Reddy's for Semaglutide Exports: Refuses Novo Nordisk Stay

In a significant development for the Indian pharmaceutical sector, the Delhi High Court (Division Bench) has today refused to stay a Single Judge's order permitting Dr. Reddy’s Laboratories (DRL) to manufacture and export Semaglutide.

This ruling comes as a setback for Danish pharma giant Novo Nordisk, the patent holder of the blockbuster drugs Ozempic and Wegovy, which had sought to completely block DRL from manufacturing the drug in India.

⚖️ The Verdict at a Glance

  • The Decision: The Division Bench (Justices C. Hari Shankar & O.P. Shukla) upheld the Single Judge's interim order.
  • The Winner (Today): Dr. Reddy’s Laboratories.
  • The Outcome: DRL can manufacture and export Semaglutide to countries where Novo Nordisk has no patent.
  • The Restriction: DRL is barred from selling the drug domestically in India until Novo's patent expires in March 2026.

The Core Dispute

Novo Nordisk holds the patent (IN’697) for Semaglutide in India, which is valid until March 2026. They argued that any manufacturing of the drug within India—even for export purposes—infringes their exclusive patent rights.

Dr. Reddy's countered that their manufacturing is solely for export to "patent-free" jurisdictions and does not harm Novo's Indian market share.

Why the Court Ruled for Dr. Reddy's

The Division Bench found Novo Nordisk’s case for an immediate stay to be "prima facie weak." Their reasoning focused on three main pillars:

  1. No Irreparable Harm: Since DRL is strictly prohibited from selling the drug in India, Novo Nordisk’s domestic market remains protected.
  2. The "Evergreening" Shadow: The court noted DRL's "credible challenge" regarding the validity of Novo's patent, citing potential issues of "evergreening" (extending a patent lifespan through minor modifications without significant therapeutic value).
  3. Balance of Convenience: Stopping DRL's export operations now would cause them significant financial loss, whereas allowing it does not directly

Comments

Popular posts from this blog

Ozempic Litigation Update: Brazil Court Confirms 2026 Patent Expiry Litigation Update: Brazil Court Confirms 2026 Expiry for Ozempic Patents Posted on December 18, 2025 The global battle over GLP-1 receptor agonist patents has reached a critical milestone in South America. In a decisive move that will reshape the obesity and diabetes market, Brazilian courts have effectively confirmed that the patent exclusivity for semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) will end in March 2026 . For pharmaceutical investors, patients, and generic manufacturers, here is the breakdown of the recent litigation landscape in Brazil. The Core Decision: Extension Denied Novo Nordisk, the manufacturer of Ozempic, had sought to extend the validity of its Brazilian patents beyond the standard 20-year term. Their argument was...
Sun Pharma vs. Novo Nordisk: Semaglutide Litigation Update (Dec 2025) The Battle for Semaglutide: Novo Nordisk vs. Sun Pharma By Pharma Insights | Updated: December 9, 2025 | Reading Time: 3 Mins The race to capture the lucrative market for Semaglutide generics has intensified in India. As of December 2025, the Delhi High Court is witnessing a flurry of legal activity involving Danish giant Novo Nordisk and Indian generic major Sun Pharmaceutical Industries . 🚨 Key Update (Dec 9, 2025): Novo Nordisk has filed a fresh plea seeking to restrain Sun Pharma from dealing in the Semaglutide compound. 1. The Core Dispute At the heart of this litigation is Indian Patent No. 262697 . Novo Nordisk, the innovator behind Ozempic and Wegovy, is seeking a permanent injunction to prevent Sun Pharma from manufacturing, selling, or exporting the active p...